As many Americans remain skeptical toward the race to release a COVID-19 vaccine, the poll examined how many respondents reported having a “great deal” and “fair amount” of trust in the pharmaceutical industry and the FDA.
Six percent of respondents reported having a great deal of trust in the pharmaceutical industry. Here are the results broken down by demographics:
- Age 18-29: 6 percent
- Age 30-49: 7 percent
- Age 50-64: 6 percent
- Age 65+: 6 percent
- White: 5 percent
- Black: 7 percent
- Latinx: 11 percent
- Rural: 4 percent
- Suburban: 6 percent
- Urban: 7 percent
Eight percent of respondents reported having a great deal of trust in the FDA. Here are the results broken down by demographics:
- Age 18-29: 9 percent
- Age 30-49: 8 percent
- Age 50-64: 9 percent
- Age 65+: 8 percent
- White: 7 percent
- Black: 9 percent
- Latinx: 13 percent
- Rural: 5 percent
- Suburban: 8 percent
- Urban: 11 percent
More articles on pharmacy:
Gilead expands oncology portfolio, acquires Immunomedics for $21B
8 considerations to take when preparing for COVID-19 vaccine distribution
‘We’re not finished with remdesivir’: Gilead CEO says trials underway for inhaled version, outpatient IV version
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
